Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

Clinical trial NCT06349317 · RECRUITING

Trial details

NCT number: NCT06349317
Sponsor: Yongyi Zeng
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Hepatocellular Carcinoma

Start date: 2024-04-22
Primary completion: 2026-05-01
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.